IGF1R Signaling Drives Antiestrogen Resistance Through PAK2/PIX Activation in Luminal Breast Cancer

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2018 Jan 23

PMID 29353882

Citations 21

Authors

Yinghui Zhang

Lynn Wester

Jichao He

Tamar Geiger

Marja Moerkens

Ram Siddappa

Jean A Helmijr

Mieke M Timmermans

Maxime P Look

Caroline H M van Deurzen

John W M Martens

Chantal Pont

Marjo de Graauw

Erik H J Danen

Els M J J Berns

John H N Meerman

Maurice P H M Jansen

Bob van de Water

Affiliations

Soon will be listed here.

Abstract

Antiestrogen resistance in estrogen receptor positive (ER) breast cancer is associated with increased expression and activity of insulin-like growth factor 1 receptor (IGF1R). Here, a kinome siRNA screen has identified 10 regulators of IGF1R-mediated antiestrogen with clinical significance. These include the tamoxifen resistance suppressors BMPR1B, CDK10, CDK5, EIF2AK1, and MAP2K5, and the tamoxifen resistance inducers CHEK1, PAK2, RPS6KC1, TTK, and TXK. The p21-activated kinase 2, PAK2, is the strongest resistance inducer. Silencing of the tamoxifen resistance inducing genes, particularly PAK2, attenuates IGF1R-mediated resistance to tamoxifen and fulvestrant. High expression of PAK2 in ER metastatic breast cancer patients is correlated with unfavorable outcome after first-line tamoxifen monotherapy. Phospho-proteomics has defined PAK2 and the PAK-interacting exchange factors PIXα/β as downstream targets of IGF1R signaling, which are independent from PI3K/ATK and MAPK/ERK pathways. PAK2 and PIXα/β modulate IGF1R signaling-driven cell scattering. Targeting PIXα/β entirely mimics the effect of PAK2 silencing on antiestrogen re-sensitization. These data indicate PAK2/PIX as an effector pathway in IGF1R-mediated antiestrogen resistance.

Citing Articles

Targeting Receptor Tyrosine Kinases as a Novel Strategy for the Treatment of Triple-Negative Breast Cancer.

Jaradat S, Ayoub N, Al Sharie A, Aldaod J Technol Cancer Res Treat. 2024; 23:15330338241234780.

PMID: 38389413 PMC: 10894558. DOI: 10.1177/15330338241234780.

SRSF5 Regulates the Expression of BQ323636.1 to Modulate Tamoxifen Resistance in ER-Positive Breast Cancer.

Tsoi H, Fung N, Man E, Leung M, You C, Chan W Cancers (Basel). 2023; 15(8).

PMID: 37190199 PMC: 10136643. DOI: 10.3390/cancers15082271.

Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile.

Smid M, Schmidt M, Prager-van der Smissen W, Ruigrok-Ritstier K, Schreurs M, Cornelissen S Breast Cancer Res. 2023; 25(1):53.

PMID: 37161532 PMC: 10169359. DOI: 10.1186/s13058-023-01653-0.

Drugging IGF-1R in cancer: New insights and emerging opportunities.

Wang P, Mak V, Cheung L Genes Dis. 2023; 10(1):199-211.

PMID: 37013053 PMC: 10066341. DOI: 10.1016/j.gendis.2022.03.002.

Hyperactivation of p21-Activated Kinases in Human Cancer and Therapeutic Sensitivity.

Sankaran D, Amjesh R, Paul A, George B, Kala R, Saini S Biomedicines. 2023; 11(2).

PMID: 36830998 PMC: 9953343. DOI: 10.3390/biomedicines11020462.

References

Santiago-Medina M, Gregus K, Gomez T . PAK-PIX interactions regulate adhesion dynamics and membrane protrusion to control neurite outgrowth. J Cell Sci. 2013; 126(Pt 5):1122-33. PMC: 3635460. DOI: 10.1242/jcs.112607. View

Sachdev D . Regulation of breast cancer metastasis by IGF signaling. J Mammary Gland Biol Neoplasia. 2008; 13(4):431-41. DOI: 10.1007/s10911-008-9105-5. View

Frank S, Bell J, Frodin M, Hansen S . A βPIX-PAK2 complex confers protection against Scrib-dependent and cadherin-mediated apoptosis. Curr Biol. 2012; 22(19):1747-54. PMC: 3470768. DOI: 10.1016/j.cub.2012.07.011. View

Beeser A, Jaffer Z, Hofmann C, Chernoff J . Role of group A p21-activated kinases in activation of extracellular-regulated kinase by growth factors. J Biol Chem. 2005; 280(44):36609-15. DOI: 10.1074/jbc.M502306200. View

Puto L, Pestonjamasp K, King C, Bokoch G . p21-activated kinase 1 (PAK1) interacts with the Grb2 adapter protein to couple to growth factor signaling. J Biol Chem. 2003; 278(11):9388-93. DOI: 10.1074/jbc.M208414200. View

Shin E, Lee C, Woo K, Quan S, Soung N, Kim Y . Phosphorylation of p85 beta PIX, a Rac/Cdc42-specific guanine nucleotide exchange factor, via the Ras/ERK/PAK2 pathway is required for basic fibroblast growth factor-induced neurite outgrowth. J Biol Chem. 2002; 277(46):44417-30. DOI: 10.1074/jbc.M203754200. View

Ring A, Dowsett M . Mechanisms of tamoxifen resistance. Endocr Relat Cancer. 2004; 11(4):643-58. DOI: 10.1677/erc.1.00776. View

Fox E, Miller T, Balko J, Kuba M, Sanchez V, Smith R . A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res. 2011; 71(21):6773-84. PMC: 3206206. DOI: 10.1158/0008-5472.CAN-11-1295. View

Tabusa H, Brooks T, Massey A . Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling. Mol Cancer Res. 2012; 11(2):109-21. DOI: 10.1158/1541-7786.MCR-12-0466. View

10.

Zhang Y, Moerkens M, Ramaiahgari S, de Bont H, Price L, Meerman J . Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res. 2011; 13(3):R52. PMC: 3218939. DOI: 10.1186/bcr2883. View

11.

Ye P, Hu Q, Liu H, Yan Y, DErcole A . beta-catenin mediates insulin-like growth factor-I actions to promote cyclin D1 mRNA expression, cell proliferation and survival in oligodendroglial cultures. Glia. 2010; 58(9):1031-41. PMC: 2917840. DOI: 10.1002/glia.20984. View

12.

Reijm E, Timmermans A, Look M, Meijer-van Gelder M, Stobbe C, van Deurzen C . High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer. Ann Oncol. 2014; 25(11):2185-2190. DOI: 10.1093/annonc/mdu391. View

13.

Jaiyesimi I, Buzdar A, Decker D, Hortobagyi G . Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol. 1995; 13(2):513-29. DOI: 10.1200/JCO.1995.13.2.513. View

14.

Lundgren K, Holm K, Nordenskjold B, Borg A, Landberg G . Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer. Breast Cancer Res. 2008; 10(5):R81. PMC: 2614516. DOI: 10.1186/bcr2150. View

15.

Jin K, Park S, Teo W, Korangath P, Cho S, Yoshida T . HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance. Cancer Discov. 2015; 5(9):944-59. PMC: 4560624. DOI: 10.1158/2159-8290.CD-15-0090. View

16.

Wang Z, Fu M, Wang L, Liu J, Li Y, Brakebusch C . p21-activated kinase 1 (PAK1) can promote ERK activation in a kinase-independent manner. J Biol Chem. 2013; 288(27):20093-9. PMC: 3707706. DOI: 10.1074/jbc.M112.426023. View

17.

Forbes J, Cuzick J, Buzdar A, Howell A, Tobias J, Baum M . Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2007; 9(1):45-53. DOI: 10.1016/S1470-2045(07)70385-6. View

18.

Jin K, Kong X, Shah T, Penet M, Wildes F, Sgroi D . The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proc Natl Acad Sci U S A. 2011; 109(8):2736-41. PMC: 3286915. DOI: 10.1073/pnas.1018859108. View

19.

Gonzalez-Malerva L, Park J, Zou L, Hu Y, Moradpour Z, Pearlberg J . High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy. Proc Natl Acad Sci U S A. 2011; 108(5):2058-63. PMC: 3033257. DOI: 10.1073/pnas.1018157108. View

20.

Luey B, May F . Insulin-like growth factors are essential to prevent anoikis in oestrogen-responsive breast cancer cells: importance of the type I IGF receptor and PI3-kinase/Akt pathway. Mol Cancer. 2016; 15:8. PMC: 4722749. DOI: 10.1186/s12943-015-0482-2. View